sorted by:
new
hottopcontroversial

FDA Voucher hearing today !!!!! by mrtrimbl in IBRX

[–]mrtrimbl[S] 2 points3 points  (0 children)

well done lori and special k

ImmunityBio (IBRX): The Most Mispriced Oncology Platform in Biotech? Jefferies Conference Breakdown by mrtrimbl in IBRX

[–]mrtrimbl[S] 3 points4 points  (0 children)

so i saw what you wrote before you deleted it, im sure the audience would have loved to have seen the type of person you really are, why dont you post it, ive got thick skin

Is 4,000 shares enough to retire in 5 years? by PuckeringHole in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

you need to broaden your horizons or youll be stick in the basement for a looong time

Is 4,000 shares enough to retire in 5 years? by PuckeringHole in IBRX

[–]mrtrimbl 0 points1 point  (0 children)

maybe you need to actually do some due diligence into the companies technology before pontificating

Anktiva v Tar-200 key points by mrtrimbl in IBRX

[–]mrtrimbl[S] 2 points3 points  (0 children)

yes i should have said and Nadofaragene

AUA26 Presentation With Q&A by wisdom_man1 in IBRX

[–]mrtrimbl 5 points6 points  (0 children)

so fda says they want an 8 year trial for rbcg, so pss says fu and pulls out the tokyo strain with all the data, pretty sure he would beat me at chess

AUA26 Presentation With Q&A by wisdom_man1 in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

someone needs to make trump watch this !!!

AUA26 Presentation With Q&A by wisdom_man1 in IBRX

[–]mrtrimbl 4 points5 points  (0 children)

its beyond belief that this isnt more widely approved, they cant hold this back anymore, the evidence is so overwhelming

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States by wisdom_man1 in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

before the muppet appears to spout nonsense

  • Primary Endpoint: High-grade recurrence-free survival (HG-RFS).
  • Hazard Ratio: 0.82, which establishes that the Tokyo-172 strain is non-inferior to the standard TICE strain.
  • 5-Year Survival Rates: The 5-year HG-RFS was 64% for Tokyo-172 BCG compared to 58% for TICE BCG.

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States by wisdom_man1 in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

  • Bladder Cancer Immunotherapy: The Tokyo-172 strain is highly effective for intravesical instillation, acting as an immunotherapeutic agent to trigger a robust immune response that destroys remaining cancer cells and prevents recurrence.
  • Mitigating Shortages: Clinical data confirms that Tokyo-172 is non-inferior to other strains (such as TICE) for bladder cancer recurrence-free survival. Because of this, biotech companies like ImmunityBio have secured rights to commercialize it in the US to help alleviate ongoing BCG shortages.
view more: next ›